Assessment of peripheral tissue perfusion disorder in streptozotocin-induced diabetic rats using dynamic contrast-enhanced MRI

Magnetic Resonance Imaging

Volumn 30, Issue 2, 2012, Pages 254-260

  Kashiwagi, Yuto ^a,b   Nodaira, Mika ^a   Amitani, Misato ^a   Murase, Kenya ^c   Abe, Kohji ^a,b  

^a SHIONOGI AND CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dynamic contrast enhanced MRI; Peripheral tissue perfusion; Streptozotocin induced diabetic rat

Indexed keywords

GADOLINIUM PENTETATE; GLUCOSE; INSULIN GLULISINE; IODOPHENAZONE C 14; SODIUM CHLORIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FOREFOOT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMAGE ANALYSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL CIRCULATION; PERIPHERAL TISSUE PERFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SIGNAL DETECTION; STREPTOZOCIN DIABETES; TISSUE BLOOD FLOW; TISSUE PERFUSION;

ANIMALS; BLOOD FLOW VELOCITY; CONTRAST MEDIA; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC FOOT; GADOLINIUM DTPA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STREPTOZOCIN;

RATTUS;

EID: 84855478980     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.09.018     Document Type: Article

References (49)

1. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19:257-267.
2. Sosenko J.M., Kato M., Soto R., Bild D.E. Comparison of quantitative sensory-threshold measures for their association with foot ulceration in diabetic patients. Diabetes Care 1990, 13:1057-1061.
3. Suzuki E., Kashiwagi A., Nishio Y., Egawa K., Shimizu S., Maegawa H., et al. Increased arterial wall stiffness limits flow volume in the lower extremities in Type 2 diabetic patients. Diabetes Care 2001, 24:2107-2114.
4. Polak J.F. Arterial sonography: efficacy for the diagnosis of arterial disease of the lower extremity. AJR Am J Roentgenol 1993, 161:235-243.
5. Orchard T.J., Strandness D.E. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18-20, 1992 New Orleans, Louisiana. Circulation 1993, 88:819-828.
6. Caputo G.R., Masui T., Gooding G.A., Chang J.M., Higgins C.B. Popliteal and tibioperoneal arteries: feasibility of two-dimensional time-of-flight MR angiography and phase velocity mapping. Radiology 1992, 182:387-392.
7. Suzuki E., Kashiwagi A., Hidaka H., Maegawa H., Nishio Y., Kojima H., et al. 1H- and 31P-magnetic resonance spectroscopy and imaging as a new diagnostic tool to evaluate neuropathic foot ulcers in Type II diabetic patients. Diabetologia 2000, 43:165-172.
8. Brurberg K.G., Benjaminsen I.C., Dørum L.M., Rofstad E.K. Fluctuations in tumor blood perfusion assessed by dynamic contrast-enhanced MRI. Magn Reson Med 2007, 58:473-481.
9. Bradley D.P., Tessier J.L., Checkley D., Kuribayashi H., Waterton J.C., Kendrew J., et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed 2008, 21:42-52.
10. Nakamura K., Taguchi E., Miura T., Yamamoto A., Takahashi K., Bichat F., et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006, 66:9134-9142.
11. Annet L., Hermoye L., Peeters F., Jamar F., Dehoux J.P., Van Beers B.E. Glomerular filtration rate: assessment with dynamic contrast-enhanced MRI and a cortical-compartment model in the rabbit kidney. J Magn Reson Imaging 2004, 20:843-849.
12. Buckley D.L., Shurrab A.E., Cheung C.M., Jones A.P., Mamtora H., Kalra P.A. Measurement of single kidney function using dynamic contrast-enhanced MRI: comparison of two models in human subjects. J Magn Reson Imaging 2006, 24:1117-1123.
13. Sari-Sarraf F., Pomposiello S., Laurent D. Acute impairment of rat renal function by L -NAME as measured using dynamic MRI. MAGMA 2008, 21:291-297.
14. Wilke N., Simm C., Zhang J., Ellermann J., Ya X., Merkle H., et al. Contrast-enhanced first pass myocardial perfusion imaging: correlation between myocardial blood flow in dogs at rest and during hyperemia. Magn Reson Med 1993, 29:485-497.
15. Eichenberger A.C., Schuiki E., Köchli V.D., Amann F.W., McKinnon G.C., von Schulthess G.K. Ischemic heart disease: assessment with gadolinium-enhanced ultrafast MR imaging and dipyridamole stress. J Magn Reson Imaging 1994, 4:425-431.
16. Atkinson D.J., Burstein D., Edelman R.R. First-pass cardiac perfusion: evaluation with ultrafast MR imaging. Radiology 1990, 174:757-762.
17. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997, 7:91-101.
18. Luo Y., Hradil V.P., Frost D.J., Rosenberg S.H., Gordon G.B., Morgan S.J., et al. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs 2009, 20:483-492.
19. Robinson S.P., McIntyre D.J., Checkley D., Tessier J.J., Howe F.A., Griffiths J.R., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003, 88:1592-1597.
20. McIntyre D.J., Robinson S.P., Howe F.A., Griffiths J.R., Ryan A.J., Blakey D.C., et al. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia 2004, 6:150-157.
21. Evelhoch J.L., LoRusso P.M., He Z., DelProposto Z., Polin L., Corbett T.H., et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004, 10:3650-3657.
22. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21:2831-2842.
23. Luo Y., Mohning K.M., Hradil V.P., Wessale J.L., Segreti J.A., Nuss M.E., et al. Evaluation of tissue perfusion in a rat model of hind-limb muscle ischemia using dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2002, 16:277-283.
24. Calcagno C., Cornily J.C., Hyafil F., Rudd J.H., Briley-Saebo K.C., Mani V., et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol 2008, 28:1311-1317.
25. Beaumont M., DuVal M.G., Loai Y., Farhat W.A., Sándor G.K., Cheng H.L. Monitoring angiogenesis in soft-tissue engineered constructs for calvarium bone regeneration: an in vivo longitudinal DCE-MRI study. NMR Biomed 2010, 23:48-55.
26. Berkowitz B.A., Roberts R., Luan H., Peysakhov J., Mao X., Thomas K.A. Dynamic contrast-enhanced MRI measurements of passive permeability through blood retinal barrier in diabetic rats. Invest Ophthalmol Vis Sci 2004, 45:2391-2398.
27. Trick G.L., Liggett J., Levy J., Adamsons I., Edwards P., Desai U., et al. Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results. Exp Eye Res 2005, 81:97-102.
28. Nagamatsu M., Nickander K.K., Schmelzer J.D., Raya A., Wittrock D.A., Tritschler H., et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995, 18:1160-1167.
29. Cameron N.E., Cotter M.A. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J Diabetes Complications 2001, 15:198-202.
30. Walker-Samuel S., Leach M.O., Collins D.J. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006, 51:3593-3602.
31. Morgan B., Utting J.F., Higginson A., Thomas A.L., Steward W.P., Horsfield M.A. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer 2006, 94(10):1420-1427.
32. Knopp M.V., Giesel F.L., Marcos H., von Tengg-Kobligk H., Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001, 12:301-308.
33. Gossmann A., Helbich T.H., Kuriyama N., Ostrowitzki S., Roberts T.P., Shames D.M., et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002, 15:233-240.
34. Drevs J., Müller-Driver R., Wittig C., Fuxius S., Esser N., Hugenschmidt H., et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002, 62:4015-4022.
35. Yankeelov T.E., Luci J.J., Lepage M., Li R., Debusk L., Lin P.C., et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005, 23:519-529.
36. Cheng H.L., Wallis C., Shou Z., Farhat W.A. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights. J Magn Reson Imaging 2007, 25:137-145.
37. Galbraith S.M., Lodge M.A., Taylor N.J., Rustin G.J., Bentzen S., Stirling J.J., et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002, 15:132-142.
38. Roberts C., Issa B., Stone A., Jackson A., Waterton J.C., Parker G.J. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006, 23:554-563.
39. Laurent D., Poirier K., Wasvary J., Rudin M. Effect of essential hypertension on kidney function as measured in rat by dynamic MRI. Magn Reson Med 2002, 47:127-134.
40. Mustafi D., Fan X., Dougherty U., Bissonnette M., Karczmar G.S., Oto A., et al. High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis. Magn Reson Med 2010, 63:922-929.
41. Rodríguez-Mañas L., Angulo J., Vallejo S., Peiró C., Sánchez-Ferrer A., Cercas E., et al. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003, 46:556-566.
42. Lucas P.D., Foy J.M. Effects of experimental diabetes and genetic obesity on regional blood flow in the rat. Diabetes 1977, 26:786-792.
43. Hu X., Sato J., Oshida Y., Xu M., Bajotto G., Sato Y. Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2003, 59:103-111.
44. Sadoff L. Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother Rep 1970, 54:457-459.
45. Kume E., Fujimura H., Matsuki N., Ito M., Aruga C., Toriumi W., et al. Hepatic changes in the acute phase of streptozotocin (SZ)-induced diabetes in mice. Exp Toxicol Pathol 2004, 55:467-480.
46. Schuhmann-Giampieri G., Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991, 26:975-979.
47. Matsumoto T., Kakami M., Noguchi E., Kobayashi T., Kamata K. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes. Am J Physiol Heart Circ Physiol 2007, 293:H1480-H1490.
48. Lin Y.R., Wu M.T., Huang T.Y., Tsai S.Y., Chung H.W., Mai V.M., et al. Comparison of arterial spin labeling and first-pass dynamic contrast-enhanced MR imaging in the assessment of pulmonary perfusion in humans: the inflow spin-tracer saturation effect. Magn Reson Med 2004, 52:1291-1301.
49. Frank L.R., Wong E.C., Haseler L.J., Buxton R.B. Dynamic imaging of perfusion in human skeletal muscle during exercise with arterial spin labeling. Magn Reson Med 1999, 42:258-267.